For the quarter ending 2025-09-30, TMDX had $65,599K increase in cash & cash equivalents over the period. $61,949K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 24,319 | 60,589 |
| Depreciation and amortization expense | 6,849 | 12,868 |
| Stock-based compensation expense | 9,136 | 18,330 |
| Non-cash interest expense and end of term accretion expense | 796 | 1,578 |
| Non-cash lease expense | 550 | 997 |
| Unrealized foreign currency transaction gains | 8 | 1,473 |
| Loss on disposal of fixed assets | 0 | -80 |
| Accounts receivable | -24,148 | 6,616 |
| Inventory | 6,902 | -5,717 |
| Prepaid expenses and other current assets | 5,900 | -1,081 |
| Other non-current assets | 6 | 4 |
| Accounts payable | 2,455 | -410 |
| Accrued expenses and other current liabilities | 13,141 | -2,413 |
| Deferred revenue | 1,735 | -192 |
| Operating lease liabilities | -740 | -1,378 |
| Net cash provided by operating activities | 69,573 | 88,754 |
| Purchases of property, plant and equipment | 7,624 | 36,113 |
| Net cash used in investing activities | -7,624 | -36,113 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,816 | 8,831 |
| Proceeds from issuance of common stock in connection with employee stock purchase plan | 1,963 | 1,286 |
| Tax withholding payments related to net settlement of restricted stock units | 138 | - |
| Net cash provided by financing activities | 3,641 | 10,117 |
| Effect of exchange rate changes on cash and restricted cash | 9 | 1,167 |
| Net increase (decrease) in cash and restricted cash | 65,599 | 63,925 |
| Cash and cash equivalents at beginning of period | 337,150 | - |
| Cash and cash equivalents at end of period | 466,674 | - |
TransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. (TMDX)